Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-09-27
2005-09-27
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S263210, C544S276000, C544S277000
Reexamination Certificate
active
06949559
ABSTRACT:
The compounds of the present invention are 2,6,9-trisubstituted purine derivatives which are inhibitors of cyclin/cdk complexes. The compounds of the current invention also are potent inhibitors of human cellular proliferation. As such, the compounds of the present invention constitute pharmaceutical compositions with a pharmaceutically acceptable carrier. Such compounds are useful in treating a disorder mediated by elevated levels of cell proliferation in a mammal compared to a healthy mammal by administering to such mammal an effective amount of the compound. Examples of the compounds of the present invention are represented by the following chemical structures:with X, Y, D, Q, V, A, R1, R2, R3, R4, and n1defined herein.
REFERENCES:
patent: 5282824 (1994-02-01), Gianturco
patent: 5866702 (1999-02-01), Mackman et al.
patent: 6316456 (2001-11-01), Meijer et al.
patent: 6413974 (2002-07-01), Dumont et al.
patent: 6479487 (2002-11-01), Dumont et al.
patent: 6627633 (2003-09-01), Trova
patent: 2002/0032327 (2002-03-01), Lum et al.
patent: 2002/0035252 (2002-03-01), Lum et al.
patent: 2002/0091263 (2002-07-01), Trova
patent: 2003/0092909 (2003-05-01), Trova
patent: 2 741 881 (1997-06-01), None
patent: 2 793 794 (2000-11-01), None
patent: 11222435 (1999-08-01), None
patent: WO 98/05335 (1998-02-01), None
patent: WO 99/07705 (1999-02-01), None
patent: WO 99/43675 (1999-09-01), None
patent: WO 99/43676 (1999-09-01), None
patent: WO 00/55161 (2000-09-01), None
Schow et al., “Synthesis and Activity of 2,6,9-Trisubstituted Purines,”Bioorganic&Medicinal Chemistry Letters7(210):2697-2703 (1997).
Imbach et al., “2,6,9-Trisubstituted Purines: Optimization Towards Highly Potent and Selective CDK1 Inhibitors,”Bioorganic&Medicinal Chemistry Letters9:91-96 (1999).
Legraverend et al., “Synthesis and in vitro Evaluation of Novel 2,6,9-Trisubstituted Purines Acting as Cyclin-Dependent Kinase Inhibitors,”Bioorganic&Medicinal Chemistry7:1281-1293 (1999).
Pérez-Roger et al., “Inhibition of Cellular Proliferation by Drug Targeting of Cyclin-Dependent Kinases,”Current Pharmaceutical Biotechnology,1:107-116 (2000).
Gray et al., “ATP-Site Directed Inhibitors of Cyclin-Dependent Kinases,”Current Medicinal Chemistry,6:859-875 (1999).
Brooks et al., “The Cell Cycle and Drug Discovery: The Promise and the Hope,”DDT,4(10):455-464 (1999).
Coleman et al., “Chemical Inhibitors of Cyclin-Dependent Kinases,” in Plattner, ed.,Annual Reports in Medicinal Chemistry,Academic Press, Inc., 32:171-179 (1997).
Mani et al., “Cyclin-Dependent Kinase Inhibitors: Novel Anticancer Agents,”Exp. Opin. Invest. Drugs,9(8):1849-1870 (2000).
Fischer et al., “Inhibitors of Cyclin-Dependent Kinases as Anti-Cancer Therapeutics,”Current Medicinal Chemistry,7:1213-1245 (2000).
Stedman,Stedman's Medical Dictionary,26thEd., Williams & Wilkins, Baltimore, Maryland, pp. 1534, 1673 (1995).
Mattsson et al., “Current Concepts in Restenosis Following Balloon Angioplasty,”Trends Cardiovasc. Med.,5(5):200-204 (1995).
Nikol et al., “Regulation of Smooth Muscle Cell Proliferation and its Possible Role in Preventing Restenosis Post- Angioplasty,”Wien Klin Wochenschr,107(13):379-389 (1995).
American Heart Association “Stenosis and Restenosis of Coronary Arteries,” http://americanheartassociation.com/ Heart_and_Stroke_A_Z_Guide/sten.html (2001).
Green et al.,Protective Groups in Organic Synthesis(Second Edition), pp. 318-319 and 331-332 (1991).
AMR Technology , Inc.
Berch Mark L.
Nixon & Peabody LLP
LandOfFree
Nitrogen substituted biaryl purine derivatives as potent... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nitrogen substituted biaryl purine derivatives as potent..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitrogen substituted biaryl purine derivatives as potent... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3435504